These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36629421)

  • 1. Design and synthesis of novel rigid dibenzo[
    El-Behairy MF; Abd-Allah WH; Khalifa MM; Nafie MS; Saleh MA; Abdel-Maksoud MS; Al-Warhi T; Eldehna WM; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157825. PubMed ID: 36629421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore-based, rationale design, and efficient synthesis of novel tetrahydrobenzo[b]thiophene candidates as potential dual Topo I/II inhibitors and DNA intercalators.
    Nofal HR; Al-Karmalawy AA; Elmaaty AA; Ismail MF; Ali AK; Abbass EM
    Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400217. PubMed ID: 38864845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Discovery of Novel Quinoxaline Derivatives as Dual DNA Intercalators and Topoisomerase II Inhibitors.
    Eissa IH; El-Naggar AM; El-Sattar NEAA; Youssef ASA
    Anticancer Agents Med Chem; 2018; 18(2):195-209. PubMed ID: 28699490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators:
    Farouk F; Elmaaty AA; Elkamhawy A; Tawfik HO; Alnajjar R; Abourehab MAS; Saleh MA; Eldehna WM; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2171029. PubMed ID: 36701269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of uracil/thiouracil based quinoline scaffolds as topoisomerases I/II inhibitors for chemotherapy: A new hybrid navigator with DFT calculation.
    El-Kalyoubi S; Elbaramawi SS; Zordok WA; Malebari AM; Safo MK; Ibrahim TS; Taher ES
    Bioorg Chem; 2023 Jul; 136():106560. PubMed ID: 37121108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
    Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2-
    El-Zoghbi MS; El-Sebaey SA; Al-Ghulikah HA; Sobh EA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2175209. PubMed ID: 36776024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Khalifa MM; Belal A; Rashed M; El-Sharkawy A; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
    Bioorg Chem; 2020 Oct; 103():104233. PubMed ID: 32882440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and discovery of new 1,2,4-triazolo[4,3-c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors.
    Alesawy MS; Al-Karmalawy AA; Elkaeed EB; Alswah M; Belal A; Taghour MS; Eissa IH
    Arch Pharm (Weinheim); 2021 Mar; 354(3):e2000237. PubMed ID: 33226150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2',3':4,5]thiazolo[3,2-
    Mourad MAE; Abo Elmaaty A; Zaki I; Mourad AAE; Hofni A; Khodir AE; Aboubakr EM; Elkamhawy A; Roh EJ; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205043. PubMed ID: 37165800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New imidazole-2-thiones linked to acenaphythylenone as dual DNA intercalators and topoisomerase II inhibitors: structural optimization, docking, and apoptosis studies.
    Mohamed AH; Alshammari MB; Aly AA; Sadek KU; Ahmad A; Aziz EA; El-Yazbi AF; El-Agroudy EJ; Abdelaziz ME
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2311818. PubMed ID: 38488131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel diindoloazepinone derivatives as DNA minor groove binding agents with selective topoisomerase I inhibition: Design, synthesis, biological evaluation and docking studies.
    Kadagathur M; Devi GP; Grewal P; Sigalapalli DK; Makhal PN; Banerjee UC; Bathini NB; Tangellamudi ND
    Bioorg Chem; 2020 Jun; 99():103629. PubMed ID: 32272367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel fused imidazotriazines acting as promising top. II inhibitors and apoptotic inducers with greater selectivity against head and neck tumors: Design, synthesis, and biological assessments.
    Al-Karmalawy AA; Rashed M; Sharaky M; Abulkhair HS; Hammouda MM; Tawfik HO; Shaldam MA
    Eur J Med Chem; 2023 Nov; 259():115661. PubMed ID: 37482023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations.
    Elwan A; Sakr H; El-Helby AA; El-Morsy A; Abdelgawad MA; Ghoneim MM; El-Sherbiny M; El-Adl K
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1556-1567. PubMed ID: 35635148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.